We have sent a notification for this news.

Also stay up to date with important news with notifications.

No thanks Yes, please

The European Medicines Agency (EMA) has positively assessed the corona vaccine AZD1222 from pharmaceutical AstraZeneca and the University of Oxford on Friday.

After that of Pfizer / BioNTech and that of Moderna, this is very likely the third vaccine to enter use in the European Union.

Only the European Commission still has to decide on the authorization of the vaccine.

This seems like a formality.

AstraZeneca and the EU have been engaged in a fight since last week because of the delay the pharmaceutical company has suffered.

The EU has ordered more than 400 million doses of AstraZeneca's corona vaccine for this year.

Before the end of March, the company would deliver the first 80 million doses, but to the EU's dismay, AstraZeneca adjusted that number to 31 million doses last week.

Production problems at a factory in Belgium are to blame, AstraZeneca claimed.

The EU is suspicious of the company and doubts whether it is fair on the supply, or whether it may deliver to other countries at the expense of Europe.

AstraZeneca CEO Pascal Soriot firmly denies this and emphasizes that the EU decided on the contract only late.

This left too little time to solve the production problems.

As a result, when authorized by the European Commission, the Netherlands will receive only 4.5 million vaccines this quarter instead of the promised 11.6 million doses.

That is another downer for the Netherlands, which is well behind the rest of the EU in terms of vaccination.

112

How the AstraZeneca vaccine could be finished so quickly by a head start

Germany has doubts about effectiveness among the over-65s

There has also been much discussion in recent days about the effectiveness of the corona vaccine AZD1222.

According to the German vaccination committee STIKO of the Robert Koch-Institut, the equivalent of the Dutch RIVM, it is unclear whether the drug works sufficiently in people over 65.

The country therefore recommends that the drug should only be administered to people under the age of 65.

The Dutch Health Council will soon also issue an advice on the use of the corona vaccine.

The Netherlands plans to use the AstraZeneca vaccine to vaccinate people under the age of 60 with medical complaints, community nurses, employees of institutions for disabled care and mental health care employees and clients.

From May onwards, adults (up to the age of 60) without medical indication would also receive the vaccine from AstraZeneca.

The United Kingdom was the first country to approve the AstraZeneca vaccine in December.

See also: Five questions about the row between AstraZeneca and the EU over the vaccine supply